Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Current Assets (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed Current Assets for 3 consecutive years, with $132.8 million as the latest value for Q4 2025.

  • Quarterly Current Assets fell 17.19% to $132.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $132.8 million through Dec 2025, down 17.19% year-over-year, with the annual reading at $132.8 million for FY2025, 17.19% down from the prior year.
  • Current Assets for Q4 2025 was $132.8 million at Inhibrx Biosciences, down from $161.4 million in the prior quarter.
  • The five-year high for Current Assets was $295.4 million in Q4 2023, with the low at $132.8 million in Q4 2025.
  • Average Current Assets over 3 years is $202.1 million, with a median of $200.7 million recorded in 2024.
  • The sharpest move saw Current Assets tumbled 45.69% in 2024, then dropped 17.19% in 2025.
  • Over 3 years, Current Assets stood at $295.4 million in 2023, then crashed by 45.69% to $160.4 million in 2024, then decreased by 17.19% to $132.8 million in 2025.
  • According to Business Quant data, Current Assets over the past three periods came in at $132.8 million, $161.4 million, and $194.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.